GLP‐1 RAs (liraglutide, semaglutide, tirzepatide) have been approved to treat obesity and provide these effects via increased insulin release, increased insulin sensitivity, decreased gastric emptying and acting on central receptors in the central nervous system (CNS) to reduce appetite [12]. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.